Literature DB >> 35419540

Clinical Course of SARS-CoV-2 Infection in Adults with ESKD Receiving Outpatient Hemodialysis.

Ana Cecilia Bardossy1, Lauren Korhonen1, Sabrina Schatzman1, Paige Gable1, Carolyn Herzig1, Nicole E Brown1, Elizabeth Beshearse1,2, Kate Varela1,2, Sarah Sabour1, Amanda K Lyons1, Rahsaan Overton1, Matthew Hudson1,2, Alfonso C Hernandez-Romieu1,2, Jorge Alvarez1, Kaylin Roman1, Mark Weng2, Elizabeth Soda1, Priti R Patel1, Crystal Grate3, Lorien S Dalrymple3, Rebecca L Wingard3, Natalie J Thornburg1, Alison S Laufer Halpin1, Jennifer M Folster1, Melissa Tobin-D'Angelo4, Janice Lea5, Ibironke Apata1,5, L Clifford McDonald1, Allison C Brown1, Preeta K Kutty1, Shannon Novosad1.   

Abstract

Background: Patients with ESKD on maintenance dialysis receive dialysis in common spaces with other patients and have a higher risk of severe SARS-CoV-2 infections. They may have persistently or intermittently positive SARS-CoV-2 RT-PCR tests after infection. We describe the clinical course of SARS-CoV-2 infection and the serologic response in a convenience sample of patients with ESKD to understand the duration of infectivity.
Methods: From August to November 2020, we enrolled patients on maintenance dialysis with SARS-CoV-2 infections from outpatient dialysis facilities in Atlanta, Georgia. We followed participants for approximately 42 days. We assessed COVID-19 symptoms and collected specimens. Oropharyngeal (OP), anterior nasal (AN), and saliva (SA) specimens were tested for the presence of SARS-CoV-2 RNA, using RT-PCR, and sent for viral culture. Serology, including neutralizing antibodies, was measured in blood specimens.
Results: Fifteen participants, with a median age of 58 (range, 37‒77) years, were enrolled. Median duration of RT-PCR positivity from diagnosis was 18 days (interquartile range [IQR], 8‒24 days). Ten participants had at least one, for a total of 41, positive RT-PCR specimens ≥10 days after symptoms onset. Of these 41 specimens, 21 underwent viral culture; one (5%) was positive 14 days after symptom onset. Thirteen participants developed SARS-CoV-2-specific antibodies, 11 of which included neutralizing antibodies. RT-PCRs remained positive after seroconversion in eight participants and after detection of neutralizing antibodies in four participants; however, all of these samples were culture negative. Conclusions: Patients with ESKD on maintenance dialysis remained persistently and intermittently SARS-CoV-2-RT-PCR positive. However, of the 15 participants, only one had infectious virus, on day 14 after symptom onset. Most participants mounted an antibody response, including neutralizing antibodies. Participants continued having RT-PCR-positive results in the presence of SARS-CoV-2-specific antibodies, but without replication-competent virus detected.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  COVID-19; ESRD; SARS-CoV-2; chronic kidney failure; dialysis; end-stage renal disease; infectiousness; infectivity; outpatients

Mesh:

Substances:

Year:  2021        PMID: 35419540      PMCID: PMC8986054          DOI: 10.34067/KID.0004372021

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  19 in total

1.  Prolonged SARS-CoV-2 Viral RNA Shedding and IgG Antibody Response to SARS-CoV-2 in Patients on Hemodialysis.

Authors:  Aisha Shaikh; Etti Zeldis; Kirk N Campbell; Lili Chan
Journal:  Clin J Am Soc Nephrol       Date:  2020-10-14       Impact factor: 8.237

2.  Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?

Authors:  Caroline Dudreuilh; Dimitrios-Anestis Moutzouris
Journal:  Am J Kidney Dis       Date:  2020-06-27       Impact factor: 8.860

3.  SARS-CoV-2: The viral shedding vs infectivity dilemma.

Authors:  Arabella Widders; Alex Broom; Jennifer Broom
Journal:  Infect Dis Health       Date:  2020-05-20

4.  Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections.

Authors:  Ger Rijkers; Jean-Luc Murk; Bas Wintermans; Bieke van Looy; Marcel van den Berge; Jacobien Veenemans; Joep Stohr; Chantal Reusken; Pieter van der Pol; Johan Reimerink
Journal:  J Infect Dis       Date:  2020-09-14       Impact factor: 5.226

5.  IgA dominates the early neutralizing antibody response to SARS-CoV-2.

Authors:  Delphine Sterlin; Alexis Mathian; Makoto Miyara; Audrey Mohr; François Anna; Laetitia Claër; Paul Quentric; Jehane Fadlallah; Hervé Devilliers; Pascale Ghillani; Cary Gunn; Rick Hockett; Sasi Mudumba; Amélie Guihot; Charles-Edouard Luyt; Julien Mayaux; Alexandra Beurton; Salma Fourati; Timothée Bruel; Olivier Schwartz; Jean-Marc Lacorte; Hans Yssel; Christophe Parizot; Karim Dorgham; Pierre Charneau; Zahir Amoura; Guy Gorochov
Journal:  Sci Transl Med       Date:  2020-12-07       Impact factor: 17.956

6.  Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.

Authors:  Anita S Iyer; Forrest K Jones; Ariana Nodoushani; Jason B Harris; Richelle C Charles; Meagan Kelly; Margaret Becker; Damien Slater; Rachel Mills; Erica Teng; Mohammad Kamruzzaman; Wilfredo F Garcia-Beltran; Michael Astudillo; Diane Yang; Tyler E Miller; Elizabeth Oliver; Stephanie Fischinger; Caroline Atyeo; A John Iafrate; Stephen B Calderwood; Stephen A Lauer; Jingyou Yu; Zhenfeng Li; Jared Feldman; Blake M Hauser; Timothy M Caradonna; John A Branda; Sarah E Turbett; Regina C LaRocque; Guillaume Mellon; Dan H Barouch; Aaron G Schmidt; Andrew S Azman; Galit Alter; Edward T Ryan
Journal:  Sci Immunol       Date:  2020-10-08

7.  Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).

Authors:  Jeroen J A van Kampen; David A M C van de Vijver; Pieter L A Fraaij; Bart L Haagmans; Mart M Lamers; Nisreen Okba; Johannes P C van den Akker; Henrik Endeman; Diederik A M P J Gommers; Jan J Cornelissen; Rogier A S Hoek; Menno M van der Eerden; Dennis A Hesselink; Herold J Metselaar; Annelies Verbon; Jurriaan E M de Steenwinkel; Georgina I Aron; Eric C M van Gorp; Sander van Boheemen; Jolanda C Voermans; Charles A B Boucher; Richard Molenkamp; Marion P G Koopmans; Corine Geurtsvankessel; Annemiek A van der Eijk
Journal:  Nat Commun       Date:  2021-01-11       Impact factor: 14.919

8.  Prolonged Live SARS-CoV-2 Shedding in a Maintenance Dialysis Patient.

Authors:  Eduardo Lacson; Daniel Weiner; Karen Majchrzak; Wendy Puryear; John Hosford; Aaron Palmer; Jonathan Runstadler; Klemens B Meyer; Doug S Johnson
Journal:  Kidney Med       Date:  2020-12-29

9.  Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States.

Authors:  Jennifer E Flythe; Magdalene M Assimon; Matthew J Tugman; Emily H Chang; Shruti Gupta; Jatan Shah; Marie Anne Sosa; Amanda DeMauro Renaghan; Michal L Melamed; F Perry Wilson; Javier A Neyra; Arash Rashidi; Suzanne M Boyle; Shuchi Anand; Marta Christov; Leslie F Thomas; Daniel Edmonston; David E Leaf
Journal:  Am J Kidney Dis       Date:  2020-09-19       Impact factor: 11.072

View more
  1 in total

1.  Collaboration between Dialysis Providers.

Authors:  Jeffrey Silberzweig; J Ganesh Bhat; Mary O Dittrich; Raghu Durvasula; Jeff Giullian; Jeffrey L Hymes; Doug Johnson; Brigitte Schiller; Richard Spech; Leslie Spry; Geoffrey Scott Walker; Suzanne Watnick; Jerry Yee; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2022-06-02       Impact factor: 14.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.